Literature DB >> 19956493

Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.

Eun Sil Park1, Kyung Hee Han, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn.   

Abstract

A 13 year-old girl with osteosarcoma and pulmonary tumor recurrence developed acute renal failure following high dose methotrexate (12 g/m(2)) therapy, she had previously tolerated high dose methotrexate and her renal and hepatic functions were normal. Briefly, 48 hours after beginning methotrexate infusion her methotrexate concentration and creatinine level were 1338.8 microM/L and 5.8 mg/dl, respectively. Grade IV oral mucositis and neutropenia with fever developed at 144 hours after MTX infusion. Hydration and alkalinization were continued and leucovorin rescue was intensified based on the plasma MTX concentrations. Plasma exchange was performed twice and hemodialysis 3 times without problems, but methotrexate and creatinine levels remained high, 91.9 microM/L, and 2.5 mg/dl, respectively. After 3 courses of hemodialysis carboxypeptidase-G2 (CPDG2) was administered at 50 U/kg, intravenously over 5 minutes. After 15 minutes of CPDG2 (Voraxaze) infusion, her plasma MTX concentration was 0.91 microM/L and no rebound elevation or side effects developed. Thirteen days post-MTX infusion her renal function had normalized. We report here our experience of a dramatic methotrexate level reduction caused by CPDG2 administration.

Entities:  

Keywords:  Acute renal failure; Carboxypeptidase-G2; High dose methotrexate; Leucovorin

Year:  2005        PMID: 19956493      PMCID: PMC2785403          DOI: 10.4143/crt.2005.37.2.133

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  12 in total

Review 1.  Methotrexate: clinical pharmacology, current status and therapeutic guidelines.

Authors:  W A Bleyer
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

2.  A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis.

Authors:  K Kawabata; H Makino; Y Nagake; H Tokioka; M Matsumi; Y Morita; K Ota; K Shikata; Z Ota
Journal:  Nephron       Date:  1995       Impact factor: 2.847

3.  Removal of methotrexate by continuous venovenous hemodiafiltration.

Authors:  P Jambou; J Levraut; C Favier; C Ichai; G Milano; D Grimaud
Journal:  Contrib Nephrol       Date:  1995       Impact factor: 1.580

4.  Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.

Authors:  B C Widemann; F M Balis; R F Murphy; J M Sorensen; M J Montello; M O'Brien; P C Adamson
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

5.  Continuous plasma resin perfusion for detoxification of methotrexate.

Authors:  J Greil; P A Wyss; K Ludwig; S Bonakdar; J Scharf; J D Beck; H Ruder
Journal:  Eur J Pediatr       Date:  1997-07       Impact factor: 3.183

6.  Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.

Authors:  B C Widemann; E Sung; L Anderson; W L Salzer; F M Balis; K S Monitjo; C McCully; M Hawkins; P C Adamson
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

7.  High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.

Authors:  Brigitte C Widemann; Frank M Balis; Beate Kempf-Bielack; Stefan Bielack; Charles B Pratt; Stefano Ferrari; Gaetano Bacci; Alan W Craft; Peter C Adamson
Journal:  Cancer       Date:  2004-05-15       Impact factor: 6.860

8.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida.

Authors:  N P Minton; T Atkinson; R F Sherwood
Journal:  J Bacteriol       Date:  1983-12       Impact factor: 3.490

10.  The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy.

Authors:  J Lankelma; E van der Klein; F Ramaekers
Journal:  Cancer Lett       Date:  1980-04       Impact factor: 8.679

View more
  5 in total

1.  Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Authors:  Jeffrey R Scott; Yinmei Zhou; Cheng Cheng; Deborah A Ward; Hope D Swanson; Alejandro R Molinelli; Clinton F Stewart; Fariba Navid; Sima Jeha; Mary V Relling; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

2.  Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.

Authors:  Anthony M Christensen; Jennifer L Pauley; Alejandro R Molinelli; John C Panetta; Deborah A Ward; Clinton F Stewart; James M Hoffman; Scott C Howard; Ching-Hon Pui; Alberto S Pappo; Mary V Relling; Kristine R Crews
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

3.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

4.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423

5.  Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study.

Authors:  Berna Demiralp; Lane Koenig; Jaya Kala; Chaoling Feng; Elizabeth G Hamlett; Marie Steele-Adjognon; Suzanne Ward
Journal:  Clinicoecon Outcomes Res       Date:  2019-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.